We would love to hear your thoughts about our site and services, please take our survey here.
Richard Marsden has to oversee with others at the top, a lot of fast moving aspects of synairgen currently. Their goal is to ensure that all trials are going smoothly perhaps sitting across two continent, ensuring production of SNG-001 is going well to meet demands and reviewing P2 at home data is nailed without many loose ends before a RNS.
If you have all information that points to good data and long terms outcomes would you pander to daily stock price movements or the ultimate goal to ensure success of your 15 years work with another 100 to 200% appreciation in stock value. Any company will ensure that the near term goal is fully successful if it brings good returns to loyal holders of company stock. They did same with P2 though they came out a bit early with results RNS without full preparation for questions onslaught.
Many who got in at 225p or 175p will feel miserable if price drops to 140p. We fully sympathise your impatience but request your patience seeing price drop from 70p to 33p in May to July as your peers in investment in SNG. However drops of 20 or 30% is immaterial to the the company as major institutions bought in more at 175p knowing what they were getting into and oversubscribed. Hence I felt it was good they did not raise money from retail at 175p who would not have fully subscribed if price was 170p. Would you have for a 5p loss ?
Novacyt I had invested from 50p had same urgency for RNS every week when it reached 170p and fell to 80p. Same when it went to 400p and fell to 225p. The CEO Graham Mullis was cursed after honest some no razmatazz interview at 110p was busy doing his job with increasing productions, doing deals, getting new tests on board and stock moved upto 1300p before it fell to current levels. Nova a Profitable gem of a UK small company now consolidating. Just giving an example that you need patience to let the intelligent and credible execs at SNG to take it up from 175p to 700p similarly.
My view of future price having raked enough with covid stocks, for SNG is
1. Very good of over 60% benefit with SNG at home to prevent hospitalisation is 360p. This is 50% of target before it comes onto market as per more informed brokers
2. ACTIV2 giving credence to p2 at home results and EUA consideration and move to p3 - next target of 720p being hit with surge of new investors World wide, before pull back till RNS of EUA SNG-001 or synterferon being available on market.
Thereafter......well history in making of a gem of a small UK company Syanirgen taking global accolades and take over.
P A T I E N C E
Many of us who got into SNG when they announced the phase 2 trail well over a year ago have seen the rise including double top at 75p on 14/4/202 & 4/5/20 at that time with news on telly and newspaper about dosing of patients. We all were there when it dropped to 33p on 16/6/20 with no news with trial ongoing silently. Acacia selling pressure was also there relentless at that time. It was 50% loss and panic for those who bought at 70p then.
All held with courage in June 2020 with only some sporadic studies giving evidence that Interferon beta 1 would help at that stage to fight covid-19. It was a long way off from the immense evidence currently, a year later, supporting IFN-ß need to fight covid-19. The price went up to 45p on 22/6/20 and we started to look forward and then it dropped again to 33p on 13/7/20. Majority held nerve and then came the defining moment on 20/7/20 and rest is history and riches for those who held on.
This is a travel down the difficult times for those of you who were not there during those days and joined later at 150p or 200p July to Nov or 100p stage in Dec. There is more evidence and support for SNG-001 and time you stopped looking at the daily gyrations in the share price as Market Makers keep the market churning as people have their own reasons to sell or buy.
Don't forget the positive data from interim analysis of SNG001 trial in COPD patients put out in September 2020 including safety of SNG-001. At home phase-2 study data results should be coming in April 1st week in all probability. They want to get the results thoroughly analysed before giving out a RNS as Richard Marsden, Professor Tom Wilkinson and Professor Stephen Holgate will be more concerned about robust evidence and all loose ends covered rather than nursing share price movements with a slightly rushed RNS about results like in July 2020. At the press conference when questions were asked about phase 2, I recall on 20/7/20 they did not have full figures for some questions asked by well clued in Journalists, which was embarrassing and they fully addressed in the Lancet paper later. They came out with a supplementary RNS on 21/7/20 also to sort some doubts that were raised.
With FDA on board and the world watching with the phase 3 trial, they surely will want to ensure that any results they put out is robust and will support the activ-2 also after the last experience. So we need to wait patiently. Trials and analysis or results take time for a small company and to run it by some peers to informally validate before putting it out in the world. This RNS will be a game changer for Synairgen and those invested. Have a huge holding in SNG despite taking profit of 30% holding at 230p levels to reinvest and wait relaxed, as we know the Professionals in Synairgen are very intelligent, respectable, honest and hard working lot.
My bad as 22/3/21 is rating of morning star and not holdings
In page you can look at only last buying details also and most end at 31 Jan 3021
https://www.morningstar.com/stocks/xlon/sng/ownership
As per Morning Star which updates holdings reasonably well - no change as of 22/3/21.
Gives maximum information of any changes
https://www.morningstar.com/stocks/xlon/sng/ownership
https://www.birminghammail.co.uk/news/uk-news/new-fears-lockdown-could-extended-20224305
Also need to remember that there are many trials ongoing in UK and competition for admitted patients is significant from trial point of view, including those fit the criteria unlike the big wave during the phase 2 in UK.
Guidelines for application of test states clearly
DHSC has a set process for the evaluation of diagnostic tests for COVID-19. If your test fulfils the DHSC evaluation process but does not yet have a UKCA, CE or CE UKNI mark, you can apply to us for a derogation. Please note that derogations will only be considered by the MHRA for COVID-19 products that are deemed critical for the National Testing Programme.
The MHRA will require confirmation of this from the DHSC before any application is considered. If you do not have a UKCA, CE or CE UKNI mark, your test will only be able to be purchased and used once a derogation has been issued by the MHRA.
AVCT LFT is critical for National Testing Programme with easy fix to alter LFT for any new strain issues.
Anyway article (not peer reviewed, preliminary work) adds to mounting evidence of interferons need to fight covid-19 virus
Marsha Rosner from the University of Chicago in Illinois and colleagues found that cannabidiol (CBD) and its metabolite 7-OH-CBD potently blocked SARS-CoV-2 replication in lung epithelial cells.
The compound also induced the expression of interferons – cell signaling proteins that are produced by host cells as an early response to viral invasion.
https://www.news-medical.net/news/20210314/Cannabis-compound-inhibits-SARS-CoV-2-replication-in-human-lung-cells.aspx?showform=cookiesettings
Citadel from Aug 2020 and Voleon Capital from Oct 2020 have had short interest in 4D.
Voleon went below 0.47% on 4/12/20 and thereafter was not tracked. They have resurfaced 10/3/21 reporting 0.52% and on 12/3/21 rising to 0.58%. So they went further short on 0.06% shares at price between 110p to 120p? Intriguing. Why would they do that with nasdaq listing next week? Were they aware of directors placing?
Even then directors such big buy is showing confidence in the company going forward, indirect inside info of good things to come.
Meanwhile is Citadel still lurking with their short not fully closed. They dropped to 0.42% on 26/2/21.
https://shorttracker.co.uk/company/GB00BJL5BR07/
A good while ago can't recollect who had posted some details here
SNG-001 Interferon 22mcg per dose is about 5 US cents at the $2500 per gram manufacturing cost level.
Making INF in the lab costs $10,000 per gram, about 20 cents per dose.
The biggest cost is the nebulizer, probably 45$ each in bulk and has been quoted at $70 each at the 10 pack level.
So overall not very costly to make and distribute with a good profit margin even at $1000 to $2000 range, let alone $3000
India came out with their own govt test which is really cheap and this led to Limited sales of Novacyt PCR kit. There was high hopes of sales of Nova PCR in India. If it was the case India and US would have had special mention in annual report of Nova. Moreover number of tests done in India is limited and lot of cheaper manpower to do individual 96 PCR plate tests with cheaper pcr machines than bulk 1000 tests with costlier BC limited to big cities.
GDR best bet is USA where only big labs doing big number automated tests is what FDA wanted. With sensitivity issues with Abbott pcr, GDR is in right place and at right time including in EU with third wave.
With small float GDR will hit the 250p soon
Surprising these experts have not researched enough to know of SNG-001 or Activ2 trial in US when they spoke yesterday.
If they had prepared for the talk surely they know of trials looking at inhaled interferon beta and phase 3 trials.
Interesting always how stocks in USA especially Biotech are so richly valued
Vir Biotech EPS loss was 14.64$ with 124m shares outstanding and went up from $40 to $64.
One wonders how Synairgen would have been valued if it was on Nasdaq with news of phase 2 success and if at home trial comes out with good success
Surely Brazil and South Africa must be on top priority of Paraxel for submission to conduct trial there due to infection numbers and variants to prove effectiveness and synairgen would want it. Let us hope that trial will start there soon as recruitment will be fast
UT explained
https://www.shiftingshares.com/what-is-an-uncrossing-trade/
The lack of transparency is the whole point of dark pools, but this is one reason why they are sometimes viewed with suspicion. There is more potential for investment fraud, unethical activity and market manipulation, especially where high-frequency traders find their way into dark pools. High-frequency trading uses computer algorithms to move in and out of positions in fractions of a second to amass a substantial gain from the tiny profits on each trade.
https://www.ii.co.uk/analysis-commentary/will-rise-dark-pool-trading-impact-retail-investors-ii512663
Is this the dark pool trading by institutions being reported after trading ends in a block report ??? Same seen on the BP after hours trade link provided a short while ago.
https://www.ii.co.uk/analysis-commentary/will-rise-dark-pool-trading-impact-retail-investors-ii512663
Billy had decent buy order for MGC at 4 which never got filled. Removed the order today as may get it cheaper for a short term punt. Don't want to chase it as it will drop in due course possibly as shares in issue is whopping 2220 million.
T'was Good picking up on Monday after my view on copper
CAML at 243p &
ANTO at 1560p
Hope GLEN crosses 300p soon. Know many are holding it here. Felt better play for copper out there and hence went with those 2.
Caused Confusion when I last made this comment
"When news of batteries becoming actual chassis of a car it will be a relatively safe bet as Elon thought of concept last year"
Should have said
UNTIL news of batteries becoming actual chassis of a car ECONOMICALLY it (Copper) will be a relatively safe bet as Elon thought of concept last year.